Skip to search formSkip to main contentSkip to account menu

BMS-275291

Known as: D2163, N-((2S)-2-Mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3-dimethyl-L-valinamide, REBIMASTAT 
A sulfhydryl-based second-generation matrix metalloproteinase (MMP) inhibitor with potential antineoplastic activity. Rebimastat selectively inhibits… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Advanced nonsmall cell lung cancer (NSCLC) is associated with venous thromboembolism (VTE). However, to the authors' knowledge… 
Highly Cited
2006
Highly Cited
2006
Background: BMS-275291 is a selective matrix metalloproteinase inhibitor (MMPI) that does not inhibit sheddases implicated in the… 
Highly Cited
2005
Highly Cited
2005
PURPOSE To determine whether BMS-275291, a broad-spectrum matrix metalloproteinase inhibitor (MMPI), added to systemic… 
Highly Cited
2004
Highly Cited
2004
Purpose: This pilot trial was performed to evaluate the safety, pharmacokinetics and feasibility of incorporating BMS-275291, a… 
Highly Cited
2004
Highly Cited
2004
Purpose: BMS-275291 is a novel broad-spectrum inhibitor of matrix metalloproteinase (MMPs) rationally designed to spare a class… 
Highly Cited
2003
Highly Cited
2003
PURPOSE The purpose of this study was to evaluate the feasibility of incorporating a novel wound angiogenesis assay into a Phase… 
Review
2003
Review
2003
  • J. Rundhaug
  • Clinical Cancer Research
  • 2003
  • Corpus ID: 30964561
The MMPs2 are a family of zinc-containing endopeptidases that degrade various components of the ECM. A number of MMPs have been… 
Review
2002
Review
2002
  • V. Poulaki
  • Current opinion in investigational drugs
  • 2002
  • Corpus ID: 39901741
Bristol-Myers Squibb (BMS) is developing BMS-275291, which is a matrix metalloproteinase (MMP) inhibitor, for the potential… 
Highly Cited
2001
Highly Cited
2001
BMS-275291 is an p.o. bioavailable, sulfhydryl-based matrix metalloproteinase (MMP) inhibitor currently in clinical development… 
Review
2001